Lead Product(s) : Ondansetron
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bekinda (RHB-102) is a proprietary, oral, bi-modal extended-release (24 hours), once-daily pill formulation of the 5-HT3 receptor antagonist antiemetic drug ondansetron.
Product Name : Bekinda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 16, 2023
Lead Product(s) : Ondansetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ondansetron
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
RedHill's RHB-102 (BEKINDA®) and Opaganib Granted New Patents in Oncology Setting
Details : Bekinda (formerly known as RHB-102) is a proprietary, bimodal release, once-daily oral pill formulation of the antiemetic drug ondansetron, targeting several gastrointestinal indications.
Product Name : Bekinda
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2023
Lead Product(s) : Ondansetron
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable